{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:42:52Z","timestamp":1792798972591,"version":"4.5.0"},"reference-count":31,"publisher":"BMJ","issue":"8","license":[{"start":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T00:00:00Z","timestamp":1739577600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"Scientific Research Program of the Shanghai Municipal Health Commission","award":["20224Y0147"],"award-info":[{"award-number":["20224Y0147"]}]},{"name":"Fund for Cross research of Shanghai Ninth People's Hospital","award":["JYJC202230"],"award-info":[{"award-number":["JYJC202230"]}],"id":[{"id":"https:\/\/ror.org\/010826a91","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272642 and 82322017"],"award-info":[{"award-number":["82272642 and 82322017"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology","award":["2022SKLE-KFKT004"],"award-info":[{"award-number":["2022SKLE-KFKT004"]}]},{"name":"Fund for Excellent Young Scholars of Shanghai Ninth People's Hospital","award":["JYYQ003"],"award-info":[{"award-number":["JYYQ003"]}],"id":[{"id":"https:\/\/ror.org\/010826a91","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Science and Technology Commission of Shanghai","award":["20DZ2270800"],"award-info":[{"award-number":["20DZ2270800"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Br J Ophthalmol"],"accepted":{"date-parts":[[2025,1,27]]},"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To compare the effect of three-drug regimen (melphalan, topotecan and carboplatin) with two-drug regimen (melphalan and topotecan) on the globe salvage outcomes of retinoblastoma (Rb) with intra-arterial chemotherapy (IAC).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study included 83 patients with 87 eyes received two-drug regimen IAC, and 95 patients with 97 eyes received three-drug regimen IAC. Propensity score matching was applied, and 84 matched (42:42) patients (eyes) were analysed. All Rb patients underwent an ophthalmologic examination before IAC using a wide-angle digital fundus camera, which was repeated monthly after the globe salvage management. Progression-free ocular survival (PFOS), relapse rate and local complications were analysed per affected eye. Analysis of overall survival (OS) and systemic complications was based on Rb individuals.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eyes treated with three-drug regimen IAC presented with higher overall PFOS than those treated with two-drug regimen IAC (p=0.026). Stratified analysis showed PFOS rate in three-drug group was higher than two-drug group among group D eyes (88.5% vs 60.6%, p=0.009). Consistently, among group E eyes, three-drug group correlated with a better PFOS, compared with two-drug group (42.9% vs 23.5%, p=0.002). There did not present with significant differences in OS (p=0.853), relapse rate (p=0.291), incidence of moderate-severe myelosuppression (grade 3\u20134, p=0.564) or ophthalmic artery obstruction (p=0.998) between these two groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Three-drug regimen was a superior IAC management compared with two-drug regiment, with improved progression-free ocular outcome for eyes of advanced retinoblastomas.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bjo-2024-326452","type":"journal-article","created":{"date-parts":[[2025,2,15]],"date-time":"2025-02-15T13:20:24Z","timestamp":1739625624000},"page":"888-893","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Effect of intra-arterial chemotherapy drug regimens on globe salvage outcomes of retinoblastoma patients"],"prefix":"10.1136","volume":"109","author":[{"given":"Xiaoyu","family":"He","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai Ninth People\u2019s Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minglei","family":"Han","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai Ninth People\u2019s Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai Ninth People\u2019s Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiwei","family":"Chai","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai Ninth People\u2019s Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Interventional Radiology and Hemangioma, Qilu Children\u2019s Hospital, Shandong University, Shandong, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7442-1391","authenticated-orcid":false,"given":"Jiayan","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai Ninth People\u2019s Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9794-4379","authenticated-orcid":false,"given":"Xuyang","family":"Wen","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai Ninth People\u2019s Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1904-5367","authenticated-orcid":false,"given":"Xianqun","family":"Fan","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Shanghai Key Laboratory of Orbital Diseases and Ocular Oncology, Shanghai Ninth People\u2019s Hospital, Shanghai JiaoTong University School of Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,2,15]]},"reference":[{"key":"2025100901550812000_109.8.888.1","doi-asserted-by":"publisher","DOI":"10.1016\/S0161-6420(96)30395-3"},{"key":"2025100901550812000_109.8.888.2","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.ajo.2005.03.037","article-title":"Effect on ocular survival of adding early intensive focal treatments to a two-drug chemotherapy regimen in patients with retinoblastoma","volume":"140","author":"Wilson","year":"2005","journal-title":"Am J Ophthalmol"},{"key":"2025100901550812000_109.8.888.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2006.06.018"},{"key":"2025100901550812000_109.8.888.4","doi-asserted-by":"publisher","DOI":"10.1111\/aos.12282"},{"key":"2025100901550812000_109.8.888.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2007.12.014"},{"key":"2025100901550812000_109.8.888.6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0034120","article-title":"Ophthalmic artery chemosurgery for less advanced intraocular retinoblastoma: five year review","volume":"7","author":"Abramson","year":"2012","journal-title":"PLoS ONE"},{"key":"2025100901550812000_109.8.888.7","doi-asserted-by":"publisher","DOI":"10.1111\/aos.13333"},{"key":"2025100901550812000_109.8.888.8","doi-asserted-by":"publisher","DOI":"10.3928\/01913913-20160719-04"},{"key":"2025100901550812000_109.8.888.9","doi-asserted-by":"publisher","DOI":"10.1080\/13816810.2016.1244695"},{"key":"2025100901550812000_109.8.888.10","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.12-9501"},{"key":"2025100901550812000_109.8.888.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2014.01.026"},{"key":"2025100901550812000_109.8.888.12","doi-asserted-by":"crossref","first-page":"e644","DOI":"10.1111\/aos.13077","article-title":"Superselective intra-arterial chemotherapy in the primary management of advanced intra-ocular retinoblastoma: first 4-year experience from a single institution in Turkey","volume":"94","author":"Tuncer","year":"2016","journal-title":"Acta Ophthalmol"},{"key":"2025100901550812000_109.8.888.13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0044322","article-title":"Combined, sequential intravenous and intra-arterial chemotherapy (bridge chemotherapy) for young infants with retinoblastoma","volume":"7","author":"Gobin","year":"2012","journal-title":"PLoS One"},{"key":"2025100901550812000_109.8.888.14","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0108692","article-title":"Risk factors for severe neutropenia following intra-arterial chemotherapy for intra-ocular retinoblastoma","volume":"9","author":"Dunkel","year":"2014","journal-title":"PLoS One"},{"key":"2025100901550812000_109.8.888.15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0156806","article-title":"Simultaneous Bilateral Ophthalmic Artery Chemosurgery for Bilateral Retinoblastoma (Tandem Therapy)","volume":"11","author":"Abramson","year":"2016","journal-title":"PLoS One"},{"key":"2025100901550812000_109.8.888.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2019.05.005"},{"key":"2025100901550812000_109.8.888.17","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.24170"},{"key":"2025100901550812000_109.8.888.18","doi-asserted-by":"publisher","DOI":"10.1007\/s10384-014-0356-y"},{"key":"2025100901550812000_109.8.888.19","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2016-309298"},{"key":"2025100901550812000_109.8.888.20","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-3768.2011.02296.x"},{"key":"2025100901550812000_109.8.888.21","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.27086","article-title":"Feasibility and results of an intraarterial chemotherapy program for the conservative treatment of retinoblastoma in Argentina","volume":"65","author":"Funes","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"2025100901550812000_109.8.888.22","doi-asserted-by":"publisher","DOI":"10.1159\/000439357"},{"key":"2025100901550812000_109.8.888.23","doi-asserted-by":"crossref","first-page":"981","DOI":"10.2147\/OPTH.S43398","article-title":"Superselective intra-arterial melphalan therapy for newly diagnosed and refractory retinoblastoma: results from a single institution","volume":"7","author":"Thampi","year":"2013","journal-title":"Clin Ophthalmol"},{"key":"2025100901550812000_109.8.888.24","doi-asserted-by":"publisher","DOI":"10.1136\/bjophthalmol-2013-303267"},{"key":"2025100901550812000_109.8.888.25","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.5332"},{"key":"2025100901550812000_109.8.888.26","doi-asserted-by":"publisher","DOI":"10.1097\/ICU.0000000000000002"},{"key":"2025100901550812000_109.8.888.27","doi-asserted-by":"crossref","first-page":"15021","DOI":"10.1038\/nrdp.2015.21","article-title":"Retinoblastoma","volume":"1","author":"Dimaras","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"2025100901550812000_109.8.888.28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0146582","article-title":"Intra-Arterial Chemotherapy (Ophthalmic Artery Chemosurgery) for Group D Retinoblastoma","volume":"11","author":"Abramson","year":"2016","journal-title":"PLoS One"},{"key":"2025100901550812000_109.8.888.29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0197081","article-title":"Ten-year experience with ophthalmic artery chemosurgery: Ocular and recurrence-free survival","volume":"13","author":"Francis","year":"2018","journal-title":"PLoS One"},{"key":"2025100901550812000_109.8.888.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2018.05.013"},{"key":"2025100901550812000_109.8.888.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2020.09.021"}],"container-title":["British Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bjo-2024-326452","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T08:56:10Z","timestamp":1760000170000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjo.bmj.com\/lookup\/doi\/10.1136\/bjo-2024-326452"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,15]]},"references-count":31,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2025,7,22]]},"published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1136\/bjo-2024-326452"],"URL":"https:\/\/doi.org\/10.1136\/bjo-2024-326452","relation":{},"ISSN":["0007-1161","1468-2079"],"issn-type":[{"value":"0007-1161","type":"print"},{"value":"1468-2079","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,15]]}}}